MAPT and Alzheimer disease: In vivo astrocyte dysfunction measured as reduced aerobic glycolysis has also been observed by PET imaging in patients with Huntington’s disease, and in individuals with preclinical AD together with accumulation of neurofibrillary tau tangles [9], adding to the evidence that astrocyte dysfunction plays an important role in the progression of neurodegenerative diseases.